Cookies That Care!
We respect your privacy and use a limited number of cookies to provide essential functionality and enhance your visit. No third-party advertising cookies involved. For more details, please read our Cookie Policy.
I need a freelancer I am a freelancer Pricing News Intelligence

> Global Directory > Journalists who Review Brands > Ozempic

Reach top Journalists who write about Ozempic
Quickly connect with experienced news professionals who write about Ozempic, ready to cover your story or provide expert reporting. From breaking news to in-depth features, find the talent you need.
Start Your Project
×
Step 1/2

Start Your Project

Connect with local news professionals in minutes.
Describe your project to get started.
12 freelancers cover Ozempic
Ozempic
Already have an account? Log in
Looking for work? Register as a Freelancer
Verify your email to complete registration
We've just sent an email to . Please check your inbox and click the link to verify your email address and complete your registration. If you don't see the email, be sure to check your spam or junk folder.
Didn't receive the email?
Ozempic
View

Ozempic

paydesk has 12 reporters who cover Ozempic. Our journalists are already on location, all over the world, and ready to work at a moment's notice. Our top correspondents who cover Ozempic are Alexis Boentes and George W Citroner. Use our journalist directory to find an Ozempic member to work for you.

Journalists Who Cover Ozempic

Alexis Boentes

Miami, United States of America
View Profile
Alexis Boentes is a journalist based in Miami, United States of America. He has worked as a Video Journalist for various media, such as international broadcaster DW en Español, in Germany.
Languages
Spanish
Services
Video Package (Web / Broadcast) Audio package (Radio / Podcast) Interview (Video / Broadcast)
+13
Topics
Business Finance Politics
+8
Related Articles
What has led to Ozempic being so accepted and recommended?
26 Nov 2024  |  Telemundo Miami (51)  |  Spanish  |  Medicare and Medicaid
Ozempic and Mounjaro are gaining popularity as effective weight loss medications, scientifically proven to reduce appetite and manage fat and sugar in the body. However, their high cost limits accessibility, with coverage through Medicare and Medicaid only for patients with diabetes or at risk of cardiovascular diseases. The Biden administration proposes expanding Medicaid coverage to over 4 million patients, reducing out-of-pocket expenses by up to 95%. This proposal, requiring a 60-day public comment period, faces potential opposition from Robert Kennedy, nominated by Donald Trump, due to concerns over government spending. Dr. Dadilia Garces emphasizes the importance of combining medication with lifestyle changes for chronic disease management.
Tags:
Ozempic Mounjaro
Balanced
Factuality Scale
Center
Political View

George W Citroner

New York, United States of America
View Profile
My work has appeared in  Fox News, Salon, Medscape, Healthline, Epoch Times, MD Magazine, Specialty Pharmacy Times, Contagion Live.
Languages
English
Services
Feature Stories Investigative Journalism Interview (Print / Radio / Podcast)
+1
Topics
Technology Science & Environment Health & Fitness
+3
Related Articles
96 Percent of Pharmacy Technicians Report Drug Shortages, Half of Patients Never Get the Medicine They Need
23 Sept 2023  |  America First Report  |  English  |  Healthcare Crisis
Pharmacy technicians across the United States report severe drug shortages affecting critical medications, including chemotherapy and diabetes drugs. Nearly half of the patients leave pharmacies without their needed medications, leading to higher healthcare costs and adverse reactions. The American Society of Health System Pharmacists highlights the need for urgent policy solutions to address the root causes of these shortages, such as supply chain disruptions and low profit margins for generic drugs. The crisis is exacerbated by staff shortages and intense competition in the pharmaceutical industry.
Tags:
Ozempic Mounjaro Wegovy
Balanced
Factuality Scale
Center
Political View

Ben Clatworthy

London, United Kingdom
View Profile
Ben Clatworthy is a journalist based in London, United Kingdom.
Languages
English
Services
Interview (Video / Broadcast) Vox Pop News Gathering
+7
Topics
Current Affairs Natural Disasters Sports
+4
Related Articles
What to expect in 2025, and some reasons to be cheerful
31 Dec 2023  |  www.thetimes.com  |  English  |  Space Exploration
The article explores various predictions and developments expected in 2025, including advancements in weight-loss drugs and cancer vaccines, potential NHS reforms by the Labour government, and significant changes in the BBC's presenter lineup. It highlights economic forecasts with potential interest rate cuts and wage growth, alongside the impact of AI and climate change initiatives. The royal family will commemorate significant anniversaries, while the travel industry sees a shift towards cooler destinations. Space exploration missions are set to advance, and educational reforms aim to improve school attendance. Overall, the article presents a mix of optimism and caution across different sectors.
Tags:
Ozempic Goldman Sachs Nationwide Building Society Halifax Google Marvel Norwegian Air Norwegian Cruise Line
Balanced
Factuality Scale
Center-Left
Political View

Hadeel Elsherief

Cairo, Egypt
View Profile
An award-winning journalist with a passion for climate and environmental issues. Based in Egypt, I have been writing for local news outlets in Egypt and Saudi Arabia since 2013, beside working for Microsoft (MSN Arabia) and Opera news application. 

 With 9 years of experience in journalism, I am ...
Languages
Arabic English French
Services
News Gathering Content Writing Research
+2
Topics
Politics Current Affairs Science & Environment
+8
Related Articles
Weight Loss, Diabetes Drugs May Pose Risks to Stomach
01 Oct 2023  |  knewz.com  |  English  |  Diabetes
A recent study published in JAMA suggests that weight loss and diabetes drugs like Wegovy and Ozempic may pose risks of serious stomach conditions, including stomach paralysis, bowel obstruction, and pancreatitis, in non-diabetic patients. Conducted by the University of British Columbia, the research highlights the importance of informed patient consent and aims to educate healthcare providers about these potential risks. The study found that GLP-1 drugs are associated with higher risks of these conditions compared to other weight loss medications, although the overall risk remains rare.
Tags:
Ozempic Wegovy GLP-1s Bupropion-naltrexone
Informative
Factuality Scale

Sergei Gapon

Copenhagen, Denmark
View Profile
Sergei Gapon is a journalist based in Copenhagen, Denmark.
12 years of experience in covering daily life, society, politics, economics, sports, art, military conflicts.
Languages
Belarusian English Russian
+1
Services
Photography Drone Footage
Topics
Politics Natural Disasters Sports
+4
Jobs Completed 1
Related Articles
Chasing weight loss dream, many in US seek Ozempic alternatives
17 Mar 2024  |  The Grand Junction Daily Sentinel  |  English  |  Medical
The article discusses Semaglutide, a drug that serves as the active ingredient in two medications: Ozempic and Wegovy. Ozempic was approved in 2017 for the treatment of diabetes, while Wegovy, also produced by Novo Nordisk, was authorized in 2021 as a medication for obesity. The focus is on the medical applications of Semaglutide in different health conditions.
Tags:
Ozempic Wegovy

Sayan Ghosh

Kolkata, India
View Profile
Sayan Ghosh is a journalist based in Kolkata, India.
Languages
English
Services
Journalism
Topics
Breaking News
Related Articles
Foods you should definitely avoid while being on Ozempic
09 Jan 2024  |  www.sportskeeda.com  |  English  |  Medication
When taking Ozempic, it's crucial to avoid foods high in fat, sugar, and calories to prevent nausea, vomiting, and blood sugar fluctuations. Opt for a diet rich in fiber, lean proteins, and low in processed foods. Avoid fatty foods, large meals, sugary foods, alcohol, junk food, and sugary drinks to help the medication work better and maintain stable blood sugar levels.
Tags:
Ozempic
Balanced
Factuality Scale

Carla Jenkins

Glasgow, United Kingdom
View Profile
I am a journalist, currently working as a reporter for Glasgow Live. Please send any stories you may have to ******.

I have had a varied background that demonstrates my versatility and skill in multiple spheres of the industry. My writing credits include writing freelance for a varied number of ...
Languages
English
Services
Journalism
Topics
Breaking News
Related Articles
Ozempic is ruining my social life (and I’m not taking it)
17 Feb 2025  |  www.thetimes.com  |  English  |  Health
The article discusses the social and health implications of using weight-loss injections like Ozempic and Mounjaro, highlighting personal experiences and concerns about their impact on social interactions and potential health risks. It mentions the increasing use of these drugs in the UK, often obtained through private prescriptions, and the recent regulatory measures to control their distribution. The author reflects on the joyless lifestyle changes these drugs bring, despite their effectiveness in weight management.
Tags:
Ozempic Mounjaro
Interpretive
Factuality Scale

Alyssa Moxley

Athina, Greece
View Profile
Alyssa Moxley is a writer and audio producer based in Athens, Greece. She is available for investigative reports, detailed cultural analysis, and interviews for print and radio. She is also available for audio recording (for radio or video) needs with high quality equipment. She has expertise in ...
Languages
English
Services
Audio package (Radio / Podcast) Interview (Video / Broadcast) Vox Pop
+9
Topics
Politics Current Affairs Technology
+8
Related Articles
The Ozempic Era of Weight Loss
18 Sept 2023  |  www.nytimes.com  |  English  |  Cultural
Ozempic, a medication initially approved for type 2 diabetes, has become widely known for its weight loss effects. It belongs to a class of drugs called GLP1s, which regulate blood sugar and insulin while also inducing weight loss. The demand for Ozempic and similar drugs like Wegovy has surged, leading to shortages and a cultural shift in discussions about obesity and weight loss. The article presents the experiences of two women, Wendy Gant and Renata Lavach-Savy, who had contrasting outcomes from using these medications. While Wendy experienced significant weight loss and a positive change in her relationship with food, Renata suffered severe side effects and a complicated relationship with food and body image. The rise of these medications raises questions about the medicalization of obesity and the potential stigma for those who choose not to use them.
Tags:
Ozempic Novo Nordisk Wegovy Mounjaro
Balanced
Factuality Scale

Jack Ramage

Manchester, United Kingdom
View Profile
Jack Ramage is a journalist based in Manchester, United Kingdom.
Languages
English
Services
Journalism
Topics
Social
Jobs Completed 2
Related Articles
What is the ricezempic diet TikTok trend, and is it really Gen Z’s dupe of Ozempic?
05 Nov 2024  |  SCREENSHOT Media  |  English  |  Health and Wellness
The ricezempic diet trend on TikTok is being compared to the diabetes medication Ozempic, claiming to suppress appetite similarly. However, experts argue that the homemade rice water drink lacks the efficacy of Ozempic and may not provide the purported health benefits. The trend highlights the influence of TikTok on dietary habits, with many users trying viral nutrition ideas despite potential adverse effects. Experts caution against such trends, emphasizing the importance of balanced nutrition and the risks of disordered eating.
Tags:
Ozempic MyFitnessPal
Balanced
Factuality Scale

Laura Sanders

Birmingham, United Kingdom
View Profile
Laura is an award-winning journalist, travel writer and broadcaster based in the West Midlands, U.K. 

She has worked with the BBC, Conde Nast Traveller, Euronews, The Independent Travel, Lonely Planet and Which? Travel, among others. Laura is a regular on the Which? podcasts offering travel ...
Languages
English
Services
Audio package (Radio / Podcast) Interview (Video / Broadcast) Feature Stories
+8
Topics
Food & Drink Investigative Reporting Research
+3
Jobs Completed 4
Related Articles
The weight-loss drug Wegovy may also help treat addiction
10 Oct 2023  |  Science News  |  English  |  Pharmaceuticals
Researchers are exploring the potential of semaglutide, a drug approved for weight loss, to treat addiction. Studies on rodents show promising results in reducing alcohol and opioid consumption. Human trials are underway, with cautious optimism from experts. The drug mimics the hormone GLP-1, affecting brain regions involved in reward and withdrawal. While the potential is significant, more extensive studies are needed to confirm efficacy and understand side effects.
Tags:
Ozempic Wegovy
Informative
Factuality Scale

Isha Sharma

Pune, India
View Profile
Looking for Yoga Instructor course? Training & Certification for Teachers.
Languages
Hindi
Services
Live Reporting Fact Checking
Topics
Health & Fitness Fact Checking
Related Articles
Ozempic Is Not The Most Effective Weight-Loss Drug On The Market, Reveals A Study
01 Oct 2023  |  www.indiatimes.com  |  English  |  Medical Research
A large-scale analysis of real-world data reveals that the diabetes drug Mounjaro is more effective for weight loss than the popular Ozempic in overweight or obese adults. The study, conducted by Truveta Research, examined healthcare data from 18,000 adults and found that Mounjaro led to more significant weight loss milestones. Both drugs are weekly injections used off-label for weight management, but Mounjaro's dual approach sets it apart. Eli Lilly is conducting ongoing clinical trials for the weight-loss counterparts of these drugs, with results expected in 2025.
Tags:
Ozempic Mounjaro Zepbound Wegovy
Factual
Factuality Scale

John Smith

Nice, France
View Profile
John Smith is a journalist based in McLean, United States of America.
Languages
Belarusian
Services
Interview (Video / Broadcast) Fact Checking
Topics
Investigative Reporting Fact Checking
Related Articles
Ozempic added to anti-doping watchlist
04 Oct 2023  |  AJP  |  English  |  Sports
Athletes will be banned from using tramadol in-competition from 1 January 2024, with Ozempic (semaglutide) being added to the World Anti-Doping Agency’s (WADA’s) monitoring list. The new WADA Prohibited List was approved, highlighting the increased scrutiny on the use of diabetes treatment Ozempic by athletes.
Tags:
Ozempic
Factual
Factuality Scale

Log in